NCT00270907View on ClinicalTrials.gov

CT-2103 in Combination With Gemcitabine in Metastatic Breast Cancer

PHASE1CompletedINTERVENTIONAL

Enrollment

13

Participants

Timeline

Start Date

December 31, 2005

Primary Completion Date

October 31, 2012

Study Completion Date

October 31, 2012

Conditions

Metastatic Breast CancerBreast Cancer

Interventions

DRUG

CT-2103

135 mg/m\^2 IV on Day 1.

DRUG

Gemcitabine

1000 mg/m\^2 IV on Day 1 and 8.

Trial Locations (1)

77030

UT MD Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

CTI BioPharma

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER

NCT00270907 - CT-2103 in Combination With Gemcitabine in Metastatic Breast Cancer | Biotech Hunter | Biotech Hunter